<2> CareDx, Inc Q4 2025 Earnings Call Summary
<3> Overview of CareDx, Inc
CareDx, Inc is a leading digital health company that specializes in the development and commercialization of innovative diagnostic solutions for transplant patients. The company’s flagship product, AlloSure, is a non-invasive test that helps monitor kidney transplant patients for rejection.
<3> Q4 2025 Earnings Call Highlights
On February 26, 2026, CareDx, Inc hosted its Q4 2025 earnings call, where the company discussed its financial performance and provided an update on its business strategy. Here are the key highlights from the call:
<3> Revenue Growth
CareDx, Inc reported revenue of $123.4 million for Q4 2025, representing a 15% increase from the same period in the previous year. The company’s revenue growth was driven by the increasing adoption of its AlloSure test, as well as the expansion of its product portfolio.
<3> Product Pipeline
CareDx, Inc has a robust product pipeline, with several new tests and technologies in development. The company’s pipeline includes a test for heart transplant patients, which is expected to launch in